Abstract | AIMS: METHODS: The present study was performed on 11 patients with stable proteinuria who were diagnosed as AA amyloidosis secondary to rheumatological diseases confirmed by renal biopsies. The study had three consecutive stages ( celecoxib 200 mg/day; indomethacin 100 mg/day; rofecoxib 25 mg/day.) Each was given for 4 weeks and a wash-out phase of 3 weeks was allowed between consecutive stages. RESULTS: CONCLUSION:
|
Authors | Serdar Kahvecioglu, Kamil Dilek, Ibrahim Akdag, Mustafa Gullulu, Celalettin Demircan, Alpaslan Ersoy, Mustafa Yurtkuran |
Journal | Nephrology (Carlton, Vic.)
(Nephrology (Carlton))
Vol. 11
Issue 3
Pg. 232-7
(Jun 2006)
ISSN: 1320-5358 [Print] Australia |
PMID | 16756637
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Cyclooxygenase 2 Inhibitors
- Indomethacin
|
Topics |
- Adult
- Amyloidosis
(classification, complications, drug therapy, urine)
- Cyclooxygenase 2 Inhibitors
(therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Indomethacin
(therapeutic use)
- Kidney
(drug effects, physiology)
- Kidney Diseases
(complications, drug therapy, physiopathology, urine)
- Male
- Proteinuria
(complications, drug therapy, urine)
|